A new type of vaccine that can be stored at warmer temperatures, removing the need for refrigeration, has been developed for mosquito-borne virus Chikungunya in a major advance in vaccine technology.
The findings, published in Science Advances today [Wednesday 25 September], reveal exceptionally promising results for the Chikungunya vaccine candidate, which has been engineered using a synthetic protein scaffold that could revolutionise the way vaccines are designed, produced and stored.
Infectious diseases continue to plague populations worldwide. Among the means at our disposal to counter this threat, vaccination has proven to be exceptionally powerful. Smallpox has been eradicated, measles, polio and tetanus constrained from the world by vaccination. However, severe challenges to human health persist, evidenced by epidemics caused by Ebola, Zika and others. This is particularly severe in developing countries which often lack adequate infrastructure and resources to prevent or manage outbreaks, bringing about disruption and damage in affected communities and massive economic shortfall.
A recent example is Chikungunya, a virus transmitted by the bite of an infected mosquito. The disease causes crippling headache, vomiting, swelling of limbs and can lead to death. Even if a fever ends abruptly, chronic symptoms such as intense joint pain, insomnia and extreme prostration remain. Formerly confined to sub-Saharan Africa, Chikungunya has recently spread worldwide as its mosquito host leaves its natural habitat due to deforestation and climate change, with recent outbreaks in USA and Europe causing alarm.
Researchers from the University of Bristol and the French National Centre for Scientific Research (CNRS) in Grenoble, France, teamed up with computer technology giant Oracle to find a way to make vaccines that are thermostable (able to withstand warm temperatures), can be designed quickly and are easily produced.
“We were working with a protein that forms a multimeric particle resembling a virus but is completely safe, because it has no genetic material inside, said Pascal Fender, expert virologist at CNRS. “Completely by chance, we discovered that this particle was incredibly stable even after months, without refrigeration.”
“This particle has a very flexible, exposed surface that can be easily engineered, added Imre Berger, Director of the Max Planck-Bristol Centre for Minimal Biology in Bristol. “We figured that we could insert small, harmless bits of Chikungunya to generate a virus-like mimic we could potentially use as a vaccine.”
To validate their design, the scientists employed cryo-electron microscopy, a powerful new technique recently installed in Bristol’s state-of-the-art microscopy facility headed by Christiane Schaffitzel, co-author of the study. Cryo-EM yields very large data sets from which the structure of a sample can be determined at near atomic resolution, requiring massive parallel computing.
Enabled by Oracle’s high-performance cloud infrastructure, the team developed a novel computational approach to create an accurate digital model of the synthetic vaccine. University of Bristol IT specialists Christopher Woods and Matt Williams, together with colleagues at Oracle, implemented software packages seamlessly on the cloud in this pioneering effort. Christopher explained: “We were able to process the large data sets obtained by the microscope on the cloud in a fraction of the time and at much lower cost than previously thought possible.”
“Researchers have had a long tradition of building and installing their own super computers on-premises, but cloud computing is allowing them to run large data sets in record time, with fast connectivity and low latency. This is helping them crunch data and make scientific breakthroughs much faster. Going forward, technologies like machine learning and cloud computing will play a significant part in the scientific world, and we are delighted we could help the researchers with this important discovery,” added Phil Bates, leading cloud architect at Oracle.
The particles the scientists designed yielded exceptionally promising results in animal studies, soundly setting the stage for a future vaccine to combat Chikungunya disease.
“We were thoroughly delighted,” continued Imre Berger. “Viruses are waiting to strike, and we need to have the tools ready to tackle this global threat. Our vaccine candidate is easy to manufacture, extremely stable and elicits a powerful immune response. It can be stored and transported without refrigeration to countries and patients where it is most needed. Intriguingly, we can now rapidly engineer similar vaccines to combat many other infectious diseases just as well.”
“It really ticks a lot of boxes,” concluded Fred Garzoni, founder of Imophoron Ltd, a Bristol biotech start-up developing new vaccines derived from the present work. “Many challenges in the industry require innovative solutions, to bring powerful new vaccines to patients. Matching cutting-edge synthetic biology with cloud computing turned out to be a winner.”
The Latest on: Synthetic vaccines
via Google News
The Latest on: Synthetic vaccines
- Single-Cell Analysis Deepens Antibody Discoveryon February 1, 2020 at 4:26 am
Such work has already led to a clinical trial of an early vaccine candidate. Briney’s group is just one of many research groups that has started using faster, higher throughput, lower cost platforms ...
- SGI-DNA Launches Vmax™ X2, the Most Innovative Product in the Competent Cells Market Since the Discovery of E. colion January 31, 2020 at 4:02 pm
Pioneering synthetic biology company, SGI-DNA, releases a new protein expression system, accelerating research into vaccines and personalized medicines by delivering up to 4x more soluble protein than ...
- Race is on as coalition sets tight timeline for coronavirus vaccineon January 29, 2020 at 4:39 pm
are bent on moving quickly with their vaccine – something they say is possible because of leaps in technology. Dr. Kobinger, Dr. Weiner and Inovio specialize in synthetic DNA vaccines, which work by ...
- Coronavirus vaccine to be developed from digital DNA sequencingon January 29, 2020 at 11:47 am
“[Our] lab is one of the groups that started the field of DNA vaccines. And in particular, we have advanced with an obvious synthetic DNA, which is the idea that you can rapidly make small pieces of ...
- Researchers Are Racing to Make a Coronavirus Vaccine. Will It Help?on January 28, 2020 at 5:44 pm
New technology and better coordination have sped up development. But a coronavirus vaccine is still months — and most likely years — away.
- Go inside the high-security lab where scientists search for a coronavirus vaccineon January 28, 2020 at 4:48 pm
Researchers also ordered ingredients to build their own synthetic version of the coronavirus, using genome sequencing information from China. But making their own would take weeks. Getting a sample of ...
- Two local labs working on developing coronavirus vaccineon January 24, 2020 at 3:23 pm
He says traditional ways to make vaccine use the actual virus, but researchers here take just the genetic code, using a computer to make a synthetic vaccine. Animal tests are already underway for ...
- How fast can biotech come up with a vaccine for the latest outbreak?on January 24, 2020 at 1:08 pm
Moderna, which has already run clinical trials on six vaccines of its own, believes it’s up to the task. The company’s technology involves creating synthetic messenger RNA that can compel the body to ...
- Saskatchewan lab joins global effort to develop coronavirus vaccineon January 24, 2020 at 1:04 am
SASKATOON — As Canadian public health agencies prepare to deal with a new viral illness, a specialized lab in Saskatoon is using its research on different strains of the coronavirus to help develop a ...
- Vaccines & Vaccination Market 2018-2028 Registering CAGR of 10.5% and Generating Revenue USD 769.4 Millionon January 23, 2020 at 4:22 am
The global vaccines & vaccination market is expected to grow at the CAGR of 10.5% during 2018-2028. The market has generated revenue of more than $ 467 million in 2018 and is projected to reach up to ...
via Bing News